# An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder.

> **NCT00228059** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 132 (actual)

## Conditions studied

- Bipolar I Disorder

## Interventions

- **DRUG:** Licarbazepine

## Key facts

- **NCT ID:** NCT00228059
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2007-07
- **Final completion:** 2007-07
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2017-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00228059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00228059, "An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00228059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*